Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10586576 | 0.84 | KDM4E (0.34) | THRBTDP1HDAC4KDM4EPKM | |
| SCHEMBL5857537 | 0.84 | LMNA (0.33) | THRBTDP1HDAC4KDM4EPKM | |
| SCHEMBL29701281 | 0.84 | KDM4E (0.34) | THRBTDP1HDAC4KDM4EPKM | |
| SCHEMBL387970 | 0.81 | L3MBTL1 (0.35) | THRBTDP1KDM4EALDH1A1 | |
| SCHEMBL8660719 | 0.81 | MEN1 (0.40) | TDP1HDAC4ALDH1A1NPSR1 | |
| SCHEMBL7109806 | 0.80 | MAPT (0.39) | HDAC4KDM4EPKMKIF11ALDH1A1 | |
| SCHEMBL9155004 | 0.80 | THRB (0.37) | THRBTDP1AKR1C1HDAC4KIF11 | |
| Hydrochloric Acid SCHEMBL28933194 | 0.79 | THRB (0.36) | THRBTDP1AKR1C1HDAC4KIF11 | |
| Oxalic Acid SCHEMBL29053840 | 0.79 | THRB (0.36) | THRBTDP1AKR1C1HDAC4KDM4E | |
| SCHEMBL9899733 | 0.77 | THRB (0.35) | THRBTDP1AKR1C1HDAC4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 444 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119930564-A | GL-V8 salt and preparation method and application thereof | 南京芩领医药科技有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-117865984-A | Naphthalene compound and preparation method and medical application thereof | 中国药科大学 | 2024-04-12 | — | — | CN | claimed |
| EP-4118145-A1 | LIQUID CRYSTAL POLYMER COMPOSITIONS AND CORRESPONDING ARTICLES | Solvay Specialty Polymers USA, LLC. (US) | 2023-01-18 | — | — | EP | claimed |
| CN-111973596-B | Anti-pulmonary fibrosis composition with improved dissolution property | 深圳市泰力生物医药有限公司 | 2022-02-15 | — | — | CN | claimed |
| EP-2841066-B1 | ANTI-INFLUENZA AGENT CONJUGATED TO ANTI-INFLAMMATORY AGENT | ACADEMIA SINICA (TW) | 2021-02-17 | — | — | EP | claimed |
| CN-112294971-A | Nilotinib compositions having improved solubility | 深圳市泰力生物医药有限公司 | 2021-02-02 | — | — | CN | claimed |
| CN-111973596-A | Anti-pulmonary fibrosis composition with improved dissolution property | 深圳市泰力生物医药有限公司 | 2020-11-24 | — | — | CN | claimed |
| CN-111467501-A | Compositions with improved dissolution properties | 深圳市泰力生物医药有限公司 | 2020-07-31 | — | — | CN | claimed |
| US-10138221-B2 | Salts of nilotinib and polymorphs thereof | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2018-11-27 | — | — | US | claimed |
| EP-3273962-A1 | CO-CRYSTALS OF A BRUTON'S TYROSINE KINASE INHIBITOR | Pharmacyclics LLC (US) | 2018-01-31 | — | — | EP | claimed |
| WO-2009155462-A1 | DETECTION OF FREE CHLORINE IN WATER | HACH COMPANY (US) | 2009-12-23 | — | — | WO | claimed |
| WO-2008077871-A1 | SALTS OF TEGASEROD | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | claimed |
| EP-1939176-A1 | Salts of Tegaserod | Novartis AG (CH) | 2008-07-02 | — | — | EP | claimed |
| WO-2007070563-A2 | STABLE SOLID FORMS OF ENTEROSTATIN | HARKNESS PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | claimed |
| US-7196214-B2 | Process for arylamine production | XEROX CORPORATION (US) | 2007-03-27 | — | — | US | claimed |
| CN-1266126-C | Phenylethanolamine derivatives for the treatment of respiratory diseases | GLAXO GROUP LTD (GB) | 2006-07-26 | — | — | CN | claimed |
| US-20060111582-A1 | Process for arylamine production | XEROX CORPORATION (US) | 2006-05-25 | — | — | US | claimed |
| EP-1606329-A1 | A PROCESS FOR THE PRODUCTION OF ACID GROUP CONTAINING POLYMER RESIN | SigmaKalon B.V. (NL) | 2005-12-21 | — | — | EP | claimed |
| WO-2004085502-A1 | A PROCESS FOR THE PRODUCTION OF ACID GROUP CONTAINING POLYMER RESIN | SIGMAKALON B.V. (NL) | 2004-10-07 | — | — | WO | claimed |
| EP-1462467-A1 | A process for the production of silyl group containing polymer resin | Sigma Kalon Services B.V. (NL) | 2004-09-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111582-A1 | Process for arylamine production | AOC2, UFM1, TYR | THRB 715/4885TDP1 4328/4885AKR1C1 3217/4885 |
| US-10138221-B2 | Salts of nilotinib and polymorphs thereof | ABL1, PTPN13, PTPN1 | THRB 2593/4885TDP1 135/4885AKR1C1 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.